Neuroprotective effect of SGLT2 inhibitors.
Open accessThe DOI matches its Crossref record; 122 of the 124 references it cites were found in a registry or an index; 21 of the 97 sources its claims cite were checked for support.
Abstract
Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective potential. SGLT2 inhibitors (SGLT2i) are lipid-soluble and reach the brain/serum ratio from 0.3 to 0.5. SGLT receptors are present in the central nervous system (CNS). Flozins are not fully SGLT2-selective and have an affinity for the SGLT1 receptor, which is associated with protection against ischemia/reperfusion brain damage. SGLT2i show an anti-inflammatory and anti-atherosclerotic effect, including reduction of proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, as well as cIMT regression. They also mitigate oxidative stress. SGLT2i improve endothelial function, prevent remodeling and exert a protective effect on the neurovascular unit, blood-brain barrier, pericytes, astrocytes, microglia, and oligodendrocytes. Flozins are also able to inhibit AChE, which contributes to cognitive improvement. Empagliflozin significantly increases the level of cerebral BDNF, which modulates neurotransmission and ensures growth, survival, and plasticity of neurons. Moreover, they may be able to restore the circadian rhythm of mTOR activation, which is quite a novel finding in the field of research on metabolic diseases and cognitive impairment. SGLT2i have a great potential to protect against atherosclerosis and cognitive impairment in patients with type 2 diabetes mellitus.
Overview
CoChat Summary
TL;DR
This narrative review summarizes proposed neuroprotective mechanisms of SGLT2 inhibitors in type 2 diabetes, atherosclerosis, and cognitive impairment, including anti-inflammatory, antioxidant, anti-atherosclerotic, AChE-inhibiting, BDNF-increasing, and mTOR-rhythm-restoring effects. It concludes that flozins have potential but that long-term clinical trials are needed to establish clinical relevance.
Key findings
- SGLT2 inhibitors are lipid-soluble and cross the blood-brain barrier, with brain/serum AUC ratios of 0.3 for canagliflozin and dapagliflozin and 0.5 for empagliflozin; SGLT1/SGLT2 are expressed in the CNS, and SGLT1 inhibition is linked to protection against ischemia/reperfusion brain damage.
- Anti-inflammatory and anti-atherosclerotic effects include reduced proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, and cIMT regression; empagliflozin reduced cIMT by 7.9% (p < 0.0001) after 3 months, and canagliflozin lowered IL-6 by 26.6% (p = 0.010) after 2 years.
- AChE inhibition may contribute to cognitive improvement: canagliflozin Ki = 0.12859 µM with estimated brain concentration ~3 µM, enough to inhibit AChE; empagliflozin Ki = 0.177 µM with brain concentration 0.5 µM, also enough; dapagliflozin Ki = 25.02 µM with brain concentration 0.3 µM, not enough.
- Empagliflozin significantly increased cerebral BDNF in db/db mice and improved cognition; in rat cerebral ischemia/reperfusion, empagliflozin dose-dependently reduced neuronal death, infarct size, and cognitive impairment via HIF-1α/VEGF signaling; SGLT2i may restore circadian mTOR activation and mimic fasting.
Methods
- Narrative review; no primary data collection or systematic search strategy is described.
- Evidence synthesized includes preclinical studies (murine/rat models, ex vivo, in silico) and selected clinical studies on SGLT2 inhibitors, atherosclerosis, inflammation, oxidative stress, mTOR signaling, cerebrovascular dysfunction, and Alzheimer’s disease pathology.
- Main analysis is a qualitative synthesis of mechanisms and reported outcomes, with one ongoing clinical trial noted: dapagliflozin in Alzheimer’s disease (NCT03801642).
Limitations
- The paper states that long-term clinical trials are necessary to establish whether the discussed mechanisms are clinically relevant, since atheroprotective and neuroprotective effects will not be immediate and require long-term SGLT2i intake.
- The paper notes that there is no available data on adverse CNS effects of flozins and that the exact mechanism of cardiovascular benefit has not been fully established.
- Evident from the text: this is a narrative review without systematic methods, and many key findings come from animal, ex vivo, or in silico studies, with limited human cognitive-outcome data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
14 Valid · 1 Not valid · 67 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 1. Introduction
What the sources say
- Supportedcites [10] Mahaffey, 2018, Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation source
The Methods (Outcomes) define the composite endpoint as cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. The Results report that canagliflozin significantly reduced that endpoint versus placebo (P=0.02 for superiority). In this sentence with three citations, this source supports the canagliflozin portion; it is not offered as evidence for the other two drugs. (LLM, conf=0.93)
- Partly supportedcites [11] Wiviott, 2019, Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Cardiovascular and Renal Outcomes section reports that dapagliflozin significantly reduced the composite of cardiovascular death or hospitalization for heart failure. It also says the reduction was driven by fewer heart-failure hospitalizations, with no difference in cardiovascular death; MACE was not significantly reduced. This paper tests dapagliflozin, not the other two drugs named alongside it. Page numbers were not supplied in the passages. (LLM, conf=0.89)
- Supportedcites [12] Bhatt, 2021, Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure, N. Engl. J. Med. source
The Methods (p. 2) define the sotagliflozin trial’s composite primary endpoint as cardiovascular death, heart-failure hospitalization, and urgent heart-failure visits. The Efficacy End Points (p. 7) report a significantly lower rate for that composite with sotagliflozin than with placebo (hazard ratio 0.67; P<0.001). This source supports the sotagliflozin portion of the multi-citation sentence; it does not establish a significant reduction in cardiovascular death on its own. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SGLT1 inhibitors are present in the pyramidal cells of the brain cortex, Purkinje cerebellum cells, hippocampus pyramidal, and granular cells [20].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 2. Neurological Potential of SGLT2 Inhibitors
What the sources say
- Partly supportedcites [20] Poppe, 1997, Expression of the Na+-D-glucose cotransporter SGLT1 in neurons, J. Neurochem. sourceExperimental — accuracy not yet measured
The 'Expression of SGLT1 protein in brain' section and Fig. 7 report SGLT1 protein in cortical pyramidal cells, hippocampal pyramidal and granular cells, and cerebellar Purkinje cells. The citing sentence says 'SGLT1 inhibitors' are present; these passages identify the protein, not inhibitors. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Among commonly used SGLT2 inhibitors, Canagliflozin has the greatest potential for inhibiting SGLT1 receptors.”
§ Neuroprotective Effect of SGLT2 Inhibitors > 2. Neurological Potential of SGLT2 Inhibitors
What the sources say
- Could not verifycites [27] Malhotra, 2015, Sodium glucose co-transporter inhibitors—A new class of old drugs, Int. J. Appl. Basic Med. Res. sourceExperimental — accuracy not yet measured
Our copy names canagliflozin only as 'the prototype drug among the newer agents' with its pharmacokinetics (PHARMACOKINETICS section), and it discusses SGLT-1/SGLT-2 selectivity in general terms (INTRODUCTION, HISTORICAL BACKGROUND, 'On fasting hypoglycemia'), but nowhere states that canagliflozin has the greatest SGLT-1 inhibitory potential among the SGLT2 inhibitors. The one place that could carry it — 'Table 1 New SGLT inhibitors and their status and selectivity' — appears in our copy only as a caption, with no table rows/indexed content, so the comparative selectivity data are not available to us. Searches for 'canagliflozin SGLT1 selectivity', 'selectivity ratio SGLT-1 versus SGLT-2 / IC50', 'Table 1 status and selectivity', and 'SGLT-1 inhibition adverse effects' returned no passage making or contradicting the claim. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans, the serum level of IL-6 dropped by 26.6% (p = 0.010) after 2 years of canagliflozin treatment [35].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 4. Inflammation
What the sources say
- Partly supportedcites [35] Heerspink, 2019, Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease, Diabetologia sourceExperimental — accuracy not yet measured
The Abstract (Results) and Table 2 of our copy do carry the exact figure: canagliflozin 300 mg/day lowered IL-6 by 26.6% (95% CI −42.0, −7.2), p = 0.010, over 2 years (104 weeks) — but explicitly as a least-squares mean percentage DIFFERENCE VERSUS GLIMEPIRIDE and only at the 300 mg dose (100 mg gave −26.3%, p = 0.011), in people with type 2 diabetes and elevated albuminuria (CANTATA-D/SU subset, n = 296). The citing sentence recasts this between-group contrast as an absolute 'drop' of 26.6% from canagliflozin treatment alone, and drops both the comparator and the dose qualifiers. It also says 'serum', whereas the Methods (Biomarker measurement) state IL-6 was measured by Luminex assay on stored PLASMA samples. The magnitude, p value and 2-year duration are faithful; the attribution of the 26.6% as a within-treatment fall in serum is not supported. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In previous studies, atherosclerotic lesions in intra- and extra-cranial arteries were associated with cognitive impairment and even dementia [2,66,67].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 3. Atherosclerosis, Cognitive Impairment, and SGLT2i
What the sources say
- Not checked yetcites [2] Dearborn, 2017, Intracranial atherosclerosis and dementia The Atherosclerosis Risk in Communities (ARIC) Study, Am. Acad. Neurol.
- Supportedcites [66] Bos, 2015, Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline, Alzheimer’s Dement. source
The Results section reports that after censoring for stroke, 'both extracranial and intracranial carotid artery calcification remained statistically significantly associated with dementia' (HR 1.32 and 1.34 per SD increase), and that larger calcification volumes were associated with cognitive decline in nondemented persons. The Abstract Conclusions and Discussion (generalized atherosclerosis 'is associated with dementia') state the same association for dementia and cognitive deterioration, matching the cited claim for both intra- and extra-cranial arteries. Minor wording differences (calcification as the atherosclerosis measure; 'cognitive decline' rather than 'cognitive impairment') do not alter the attributed content. (LLM, conf=0.88)
- Partly supportedcites [67] Wingo, 2020, Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain, Nat. Neurosci. sourceExperimental — accuracy not yet measured
The Abstract/Introduction of our copy supports the intracranial half of the claim: cerebral atherosclerosis is defined as plaques in 'the walls of large arteries in the brain' and is stated to be among the earliest changes associated with development of AD dementia, with ~three times higher risk for AD and nine times higher risk for vascular dementia (Abstract, p. 1). The METHODS confirm the paper's own atherosclerosis assessment covered only intracranial vessels — visual grading of the Circle of Willis (vertebral, basilar, posterior, middle and anterior cerebral arteries and proximal branches), not extracranial arteries (METHODS, ROS/MAP section). No passage in our copy addresses atherosclerotic lesions in extra-cranial arteries and cognition (searched: 'extracranial carotid atherosclerosis', 'carotid artery atherosclerosis systemic extracranial vessels'), so that part of the citing sentence is not supported by this source. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
42 more claims · 2 with their cited sources checked
Create a free account to see all 93 claims and to verify the 76 references still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 6
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, SGLT2is have demonstrated neuroinflammatory and antioxidative effects in addition to cardiovascular prevention.56”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [56]
Citations
Cites
1 retracted
Xue, L., Yuan, X., Zhang, S., & Zhao, X. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9388562 · Cited by 20
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“In the CANTOS study, inhibition of interleukin-1β with canakinumab significantly reduced cardiovascular risk independently of lipid levels [78].”
BackgroundDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 1×
“The exact mechanism has not been fully established yet, and SGLT2 inhibitors show many additional beneficial effects which contribute to their wider use, even in non-diabetic patients [14].”
BackgroundReactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897 · cited 4×
“The overproduction of ROS or decrease in the anti-oxidant defense results in oxidative stress, which is a significant contributor to vascular diseases, including atherosclerosis, as it causes endothelial dysfunction, promotes remodeling and further enhances inflammation [94].”
BackgroundInfluentialO'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 1×
“It is a crucial element of the innate immune system activated not only by microbial infection or cellular damage but also by chronic inflammatory diseases, including atherosclerosis and Alzheimer’s disease [80].”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease causing a variety of complications, including atherosclerosis which is associated with increased cardiovascular risk contributing to reduced life expectancy [1].”
BackgroundSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · cited 1×
“It is even called a “dual SGLT1/SGLT2 inhibitor”, however, it is the newest Flozin, and it is not yet used in diabetic patients on a large scale [12].”
Background
Research works printed but not linked: 1
- Esterline, R., Oscarsson, J., and Burns, J. (2020). International Review of Neurobiology, Elsevier Inc.. [1st ed.].
Cited by
Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14313 · Cited by 180
Mone, P., Lombardi, A., Gambardella, J., Pansini, A., Macina, G., Morgante, M., Frullone, S., & Santulli, G. (2022) · Diabetes Care · doi:10.2337/dc21-2434 · Cited by 151
Inflammatory Mechanisms of Diabetes and Its Vascular Complications
Nedosugova, L. V., Markina, Y. V., Бочкарева, Л. А., Кузина, И. А., Petunina, N. A., Yudina, I. Y., & Kirichenko, T. V. (2022) · Biomedicines · doi:10.3390/biomedicines10051168 · Cited by 156
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Kotecha, P., Svensson, M., Bian, J., & Guo, J. S. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0353 · Cited by 116
Mei, J., Li, Y., Niu, L., Liang, R., Tang, M., Cai, Q., Xu, J., Zhang, D., Yin, X., Liu, X., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00431-y · Cited by 98
“Neuroinflammation is closely related to cognitive deficits [5].”
BackgroundCardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
Seminer, A., Mulihano, A., O’Brien, C., Krewer, F., Costello, M., Judge, C., O’Donnell, M., & Reddin, C. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0360 · Cited by 91
Dong, M., Wen, S., & Zhou, L. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s375559 · Cited by 90
The insulin resistant brain: impact on whole-body metabolism and body fat distribution
Heni, M. (2024) · Diabetologia · doi:10.1007/s00125-024-06104-9 · Cited by 89
“While SGLT2 is expressed in the brain [99], it is unclear whether these pharmacological inhibitors act there directly or indirectly via peripheral action with subsequent projections towards the brain [98, 99].”
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
Heimke, M., Lenz, F., Rickert, U., Lucius, R., & Cossais, F. (2022) · Cells · doi:10.3390/cells11193107 · Cited by 78
“Although a clinical randomized trial of the SGLT2 inhibitor dapagliflozin in patients with AD is currently being conducted (NCT03801642), to our knowledge, similar studies have not yet been performed for empagliflozin [16].”
BackgroundInfluentialArmillotta, M., Angeli, F., Paolisso, P., Belmonte, M., Raschi, E., Dalmazi, G. D., Amicone, S., Canton, L., Fedele, D., Suma, N., et al. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108861 · Cited by 84
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Kim, H., Biessels, G. J., Yu, M. H., Hong, N., Lee, Y., Lee, B., Kang, E. S., Soo, B., Lee, E. J., & Lee, M. (2024) · Neurology · doi:10.1212/wnl.0000000000209805 · Cited by 76
Youn, Y. J., Kim, S. Y., Jeong, H., Ah, Y., & Yu, Y. M. (2024) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2024.101131 · Cited by 76
Lee, S. A., & Riella, L. V. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.02.1435 · Cited by 71
“106 The use of SGLT2 inhibitors can mediate a neuro-protective effect either by directly modulating central nervous system in fl ammation or indirectly by ameliorating the systemic in fl ammation outside the central nervous system.”
BackgroundResearch advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus
Zhang, R., Xie, Q., Lu, X., Fan, R., & Tong, N. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01325-9 · Cited by 65
“This process assumes significant relevance in the pathogenesis of diabetic TOD [57].”
BackgroundTargeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
Ghosh, P., Fontanella, R. A., Scisciola, L., Pesapane, A., Taktaz, F., Franzese, M., Puocci, A., Ceriello, A., Prattichizzo, F., Rizzo, M. R., et al. (2023) · Theranostics · doi:10.7150/thno.86831 · Cited by 73
“Numerous scientific evidences highlight a strong correlation between oxidative stress, beta-amyloid aggregation, neuroinflammation, and neurodegeneration [25, 26].”
BackgroundMohammed, N. N., Tadros, M. G., & George, M. Y. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01384-w · Cited by 64
“EMPA was reported previously for its possible neuroprotective effects (Pawlos et al. 2021).”
BackgroundZhao, N., Yu, X., Zhu, X., Song, Y., Gao, F., Yu, B., & Qu, A. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10470-x · Cited by 68
Yang, L., Zhang, X., & Wang, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.992937 · Cited by 61
“In addition, aberrant activation of the NLRP3 inflammasome is related to several types of inflammatory diseases, including obesity (45), diabetes (46, 47), atherosclerosis (8, 48, 49), nonalcoholic steatohepatitis (50), gout (51–53), and Alzheimer’s disease (54, 55).”
BackgroundZhou, X., Chen, K., Hu, Y., & Wang, X. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1021378 · Cited by 61
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 69
“Most SGLT2 inhibitors are lipid-soluble and effectively cross the blood–brain barrier [166].”
Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
Scheen, A. J., & Bonnet, F. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101419 · Cited by 51
Yonamine, C. Y., Michalani, M. L. E., Moreira, R. J., & Machado, U. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216480 · Cited by 54
Cognitive impairment in CKD patients: a guidance document by the CONNECT network
Bolignano, D., Simeoni, M., Hafez, G., Pépin, M., Gallo, A., Altieri, M., Liabeuf, S., Giannakou, K., De, A., Capasso, G., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae294 · Cited by 59
“These include enhancing glycaemic control, exerting anti-atherosclerotic and anti-inflammatory effects, improving cerebrovascular function, modulating neurotransmitter systems and potentially exhibiting neuroprotective properties by increasing BDNF [130 , 131 ].”
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Bendotti, G., Montefusco, L. B., Pastore, I., Lazzaroni, E., Lunati, M. E., & Fiorina, P. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02162-9 · Cited by 53
“Dapagliflozin, empagliflozin, and ertugli-flozin have a larger affinity for SGLT-2 than SGLT-1, while canagliflozin and sotagliflozin are most selective for SGLT-1 [17].”
BackgroundRelevance of Sugar Transport across the Cell Membrane
Carbó, R., & Rodríguez, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076085 · Cited by 47
“This transporter plays a vital role in circulating glucose from blood to the brain parenchyma through the brain–blood barrier (BBB) [39].”
Santulli, G., Sabatelli, G., Wang, B., Savino, M., Bruno, F. P., Jankauskas, S. S., Massaro, A., Peluso, C., Vicario, M., Savino, L., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03022-x · Cited by 53
“In addition, SGLT2 inhibitors may improve cognitive impairment through more direct neuro-protective mechanisms, including acetyl-cholinesterase inhibition and increase in cerebral levels of brain-derived neurotrophic factor [246].”
SGLT2 Inhibitors in Kidney Diseases—A Narrative Review
Gajewska, A., Wasiak, J., Sapeda, N., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094959 · Cited by 48
“These properties speak of their neuroprotective effect [63].”
BackgroundNiu, Y., Zhang, Y., Zhang, W., Lu, J., Chen, Y., Hao, W., Zhou, J., Wang, L., & Xie, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.820541 · Cited by 42
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Tharmaraja, T., Ho, J. S. Y., Sia, C., Lim, N.-A., Chong, Y. F. V., Lim, A. Y. L., Rathakrishnan, R., Yeo, L. L. L., Sharma, V. K., & Tan, B. Y. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221086996 · Cited by 42
Khedr, L. H., Eladawy, R. M., Nassar, N. N., & Saad, M. A. E. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109293 · Cited by 39
Lardaro, A., Quarta, L., Pagnotta, S., Sodero, G., Mariani, S., Ben, M. D., Desideri, G., Ettorre, E., & Baratta, F. (2024) · Biomedicines · doi:10.3390/biomedicines12081750 · Cited by 39
“SGLT receptors are expressed in brain regions involved in the learning process and food intake regulation, and SGLT2i exert neurological beneficial effects by which gliflozins might improve cognitive function in subjects with diabetes mellitus and Alzheimer’s disease (AD) [13].”
BackgroundChauhan, A., Dubey, S., & Jain, S. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4111 · Cited by 37
Piątkowska‐Chmiel, I., Herbet, M., Gawrońska‐Grzywacz, M., Pawłowski, K., Ostrowska-Leśko, M., & Dudka, J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06341-7 · Cited by 36
Rathmann, W., & Kostev, K. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01943-7 · Cited by 32
Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder
Nakhal, M. M., Aburuz, S., Sadek, B. S., & Akour, A. A. (2022) · Molecules · doi:10.3390/molecules27217174 · Cited by 33
Alzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 35
“…mechanisms of SGLT2 inhibitors, they have the molecular ability to inhibit acetylcholinesterase (AChE), thereby supporting synaptic function and neurotransmission, especially in patients with AD, as they have a reduced amount of acetylcholine neurotransmitters in the central nervous system [22].”
Mancinetti, F., Xenos, D., Fano, M. D., Mazzieri, A., Porcellati, F., Boccardi, V., & Mecocci, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102018 · Cited by 37
Jaiswal, V., Mashkoor, Y., Raj, N., Rajak, K., Jaiswal, A., & Fonarow, G. C. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.06.030 · Cited by 34
“18 Although SGLT2i users generally showed better cardiovascular and renal outcomes than nonusers in the included studies, the incidence of dementia and Parkinson’s disease was similar between the 2 groups.”
Khamies, S. M., El-Yamany, M. F., & Ibrahim, S. M. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10140-y · Cited by 34
“…of CAN to the SAD group attenuated these histopathological changes, which is in harmony with previous studies that CAN could reduce astro-gliosis and microgliosis in the hippocampus, in addition to exerting protection on the neurovascular unit (Pawlos et al. 2021; Jayarathne et al. 2022).”
He, Z., & Sun, J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106772 · Cited by 35
Gunawan, P. Y., Gunawan, P. A., & Hariyanto, T. I. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01538-1 · Cited by 32
“The administration of SGLT2 inhibitors impedes the remodeling of several components of the neurovascular unit, including the blood–brain barrier, pericytes, astrocytes, microglia, and oligodendrocytes [34, 36].”
BackgroundInfluentialA Correlative Relationship Between Heart Failure and Cognitive Impairment: A Narrative Review
Park, M. S., & Kim, E. J. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e334 · Cited by 36
“101”
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
“Likewise, there is mounting evidence that SGLT-2 inhibitors have neuroprotective properties [85,87].”
BackgroundPharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Adem, M. A., Decourt, B., & Sabbagh, M. N. (2024) · Biomedicines · doi:10.3390/biomedicines12010099 · Cited by 34
“Empagliflozin has also been shown to increase the levels of cerebral brain-derived neurotrophic factor (BDNF) in db/db mice, which ensures neuronal growth, survival, and plasticity [157].”
Backgroundyanchen, L., Cheng, X., & Dong, Q. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02255-6 · Cited by 31
“In addition, emerging reports have suggested that SGLT2 inhibitors have a neuroprotective effect on critical pathological alterations caused by CSVD, such as the loss of myelin and endothelial integrity [17].”
BackgroundCannarella, R., Condorelli, R. A., Leanza, C., Garofalo, V., Aversa, A., Papa, G., Calogero, A. E., & Vignera, S. L. (2023) · Diabetic Medicine · doi:10.1111/dme.15217 · Cited by 28
“11,22 Zelniker and colleagues, in their systematic review and meta-analysis, demonstrated that SGLT2is reduce the rate of hospitalization for heart failure and progression of renal disease.”
BackgroundTrujillo-Rangel, W. Á., Acuña-Vaca, S., Padilla-Ponce, D. J., García-Mercado, F. G., Torres-Mendoza, B. M., Pacheco-Moisés, F. P., Escoto-Delgadillo, M., García‐Benavides, L., & Delgado-Lara, D. L. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084401 · Cited by 31
“These effects may contribute to protecting against cognitive decline [33,79,80].”
BackgroundLiao, L., Zhang, L., Yang, C., Wang, T., Feng, L., Peng, C., Long, Y., Dai, G., Chang, L., Yan, W., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106598 · Cited by 28
“…SOTA, empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin, have been shown to exhibit neuro-protective effects such as anti-inflammatory properties, mitigating oxidative stress, improving endothelial function, producing ketone metabolites (Koutentakis et al., 2023; Pawlos et al., 2021).”
BackgroundMuhammad, R. N., Albahairy, M. A., Fattah, M. A. A. E., & Ibrahim, W. W. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06663-0 · Cited by 27
“In fact, the inflammatory response can start in the periphery and culminate in the brain or break out within the CNS under certain stimuli.”
InfluentialElian, V., Popovici, V., Karampelas, O., Pîrcălăbioru, G. G., Radulian, G., & Muşat, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041972 · Cited by 26
Metabolic Syndrome, Kidney-Related Adiposity, and Kidney Microcirculation: Unraveling the Damage
Jang, K. W., Hur, J., Lee, D. W., & Kim, S. R. (2024) · Biomedicines · doi:10.3390/biomedicines12122706 · Cited by 28
SGLT2 and SGLT1 inhibitors suppress the activities of the RVLM neurons in newborn Wistar rats
Oshima, N., Onimaru, H., Yamashiro, A., Goto, H., Tanoue, K., Fukunaga, T., Sato, H., Uto, A., Matsubara, H., Imakiire, T., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01417-5 · Cited by 25
“However, Al Hamed et al. [5] show that SGLT2 inhibitors are partially lipid soluble medicines and can cross the BBB, and Pawlos et al. [23] show that SGLT2 inhibitors reach the brain/serum ratio from 0.3 to 0.5.”
InfluentialSGLT inhibitors for improving Healthspan and lifespan
O’Keefe, J. H., Weidling, R., O’Keefe, E. L., & Franco, W. G. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.10.003 · Cited by 27
Tang, H., Donahoo, W. T., Svensson, M., Shaaban, C. E., Smith, G. E., Jaffee, M. S., Huang, Y., Hu, X., Lu, Y., Salloum, R. G., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14048 · Cited by 26
Kamel, A. S. E. D., Wahid, A. M., Abdelkader, N. F., & Ibrahim, W. W. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121002 · Cited by 24
Ni, W., Niu, Y., Cao, S., Fan, C., Fan, J., Zhu, L., & Wang, X. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03160-1 · Cited by 24
“Downregulation of STAT1 attenuates atherosclerosis and cognitive impairment in T2DM patients [60].”
BackgroundErichsen, J. M., Register, T. C., Sutphen, C. L., Ma, D., Gaussoin, S. A., Rudolph, M. D., Rundle, M. M., Bateman, J. T., Lockhart, S. N., Sai, K. K. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70704 · Cited by 29
Ding, J., Shi, Q., Tao, Q., Su, H., Du, Y., Pan, T., & Zhong, X. (2023) · PeerJ · doi:10.7717/peerj.16698 · Cited by 24
“Pawlos et al. (2021) found that SGLT2 inhibitors are fat-soluble and cross the blood–brain barrier to reach various parts of the brain.”
BackgroundAbdelsalam, R. M., Hamam, H. W., Eissa, N. M., El-Sahar, A. E., & Essam, R. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04499-5 · Cited by 22
Adhikari, U., Gad, H., Chatterjee, D., Malhotra, C., Bhadada, S. K., Malik, R. A., & Rastogi, A. (2025) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70011 · Cited by 23
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101623 · Cited by 24
Wang, J., Shi, H., Yang, Y. S., & Gong, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1505794 · Cited by 30
“Sodium-glucose cotransporters (SGLTs) are transmembrane proteins crucial for transporting sodium ions and glucose (264).”
Atiya, A., Gupta, D. D., Alsayari, A., Alrouji, M., Alotaibi, A., Sharaf, S. E., Abdulmonem, W. A., Alorfi, N. M., Abdullah, K. M., & Shamsi, A. (2023) · ACS Omega · doi:10.1021/acsomega.2c06634 · Cited by 21
“21 Here, we employed structure-based virtual screening to find potential inhibitors of MARK4.”
Yılmaz, H., & Bayraktutan, U. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040232 · Cited by 21
“Reduced neuroinflammation in turn leads to diminished WMH levels and BBB permeability [135,143].”
Cozza, A., Chinigò, C., Filicetti, E., Greco, G. I., Lappano, R., Marinaro, C., Muglia, L., Soraci, L., Corsonello, A., Lattanzio, F., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102834 · Cited by 20
Kowalska, K., Wilczopolski, P., Buławska, D., Młynarska, E., Rysz, J., & Franczyk, B. (2022) · Antioxidants · doi:10.3390/antiox11122500 · Cited by 23
“Flozins may bring neuroprotective effects through several mechanisms, including their anti‐inflammatory and anti‐atherosclerotic properties, reduction in oxidative stress, amelioration cerebrovascular remodelling and restoring a balance between catabolism and anabolism [59,60].”
Is it time to repurpose geroprotective diabetes medications for prevention of dementia?
He, D., & Aleksić, S. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18405 · Cited by 20
Dipeptidyl peptidase-4 inhibitors alleviate cognitive dysfunction in type 2 diabetes mellitus
Meng, J., Yan, R., Zhang, C., Bai, X., Yang, X., Yu, Y., Feng, T., & Liu, X. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01985-y · Cited by 21
“An increased understanding of the common pathology between diabetes and cognitive disorders has led to a focus on the therapeutic potential of antidiabetic agents for treating cognitive dysfunction [16–20].”
BackgroundElariny, H. A., Kabel, A. M., Selim, H. M. R. M., Helal, A. I., Abdelrahman, D., Borg, H. M., Elkady, M. A., Dawood, L. M., El‐Badawy, M. F., Almalawi, H. F. A., et al. (2024) · Medicina · doi:10.3390/medicina60111805 · Cited by 23
“Future research efforts should be directed towards a more in-depth investigation of the effects of different doses of canagliflozin on these mechanisms and to provide a reliable evaluation of the benefits of its clinical application.”
Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
Wołos-Kłosowicz, K., Matuszewski, W., Rutkowska, J., Krankowska, K., & Bandurska-Stankiewicz, E. M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206183 · Cited by 19
“Recent findings have confirmed SGLT-2 inhibitors’ neuroprotective properties in terms of central nervous system pathologies and cognitive impairment [73], mechanisms of which might theoretically coincide in DR.”
BackgroundPathophysiological role and potential drug target of NLRP3 inflammasome in the metabolic disorders
Hu, H., Wang, S., & Chen, C. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111320 · Cited by 18
Metabolic Modulators in Depression: Emerging Molecular Mechanisms and Therapeutic Opportunities
Dyndał, K., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178755 · Cited by 19
“Recent studies have shown their beneficial impact on the brain [100].”
Pleiotropic effects of SGLT2 inhibitors: A focus on macrophage-mediated action
Shu, B., Chen, X., Liu, Z., Tang, H., Yang, B., & Fu, C. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108046 · Cited by 21
Diabetes mellitus associated neurovascular lesions in the retina and brain: A review
Sinclair, S. H., Miller, E. S., Talekar, K. S., & Schwartz, S. S. (2022) · Frontiers in Ophthalmology · doi:10.3389/fopht.2022.1012804 · Cited by 21
Ünal, İ., Cansız, D., Beler, M., Sezer, Z., Güzel, E., & Emekli‐Alturfan, E. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148536 · Cited by 18
Chen, Y., Chang, H., Lin, Y., Chien, K., Hsieh, Y., Chung, F., Lin, C., Lip, G. Y. H., & Chen, S. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3775 · Cited by 20
“31 34 Previous literature mainly compared the efficacy between SGLT2i and DPP4i in reducing the risk of incident dementia.”
BackgroundAbdelaziz, A. M., Rasheed, N. O. A., Zaki, H. F., Salem, H. A., & El‐Sayed, R. M. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113839 · Cited by 22
Katsurada, K. (2025) · Hypertension Research · doi:10.1038/s41440-025-02216-w · Cited by 17
Burns, J. M., Morris, J. K., Vidoni, E. D., Wilkins, H., Choi, I., Lee, P., Hunt, S. L., Mahnken, J. D., Brooks, W. M., Lepping, R. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70416 · Cited by 19
Shim, B., Stokum, J. A., Moyer, M., Tsymbalyuk, N., Tsymbalyuk, O., Keledjian, K. M., Ivanova, S., Tosun, Ç., Gerzanich, V., & Simard, J. M. (2023) · Cells · doi:10.3390/cells12182221 · Cited by 17
“The data presented here and previously [66,67] indicate that SGLT2 inhibitors also have potentially important protective effects in acute ischemic stroke.”
BackgroundProspects of antidiabetic drugs in the treatment of neurodegenerative disease
Hu, L., Wang, W., Chen, X., Bai, G., Ma, L., Yang, X., Shu, Q., & Li, X. (2024) · Brain‐X · doi:10.1002/brx2.52 · Cited by 20
Abdelaziz, H. A., Hamed, M. F., Ghoniem, H. A., Nader, M. A., & Suddek, G. M. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10162-6 · Cited by 18
García-Zamora, M., García‐Lluch, G., Moreno, L., Pardo, J., & Cháfer-Pericas, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107295 · Cited by 16
The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function
Kantreva, K., Katsaounou, P. A., Saltiki, K., Trakada, G., Ntali, G., Stratigou, T., Tzanela, M., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-04033-6 · Cited by 18
Zhang, Y., Xie, P., Li, Y., Chen, Z., & Shi, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142003 · Cited by 16
“Therefore, quantifying the inhibitory effect on SGLT transporters in the brain and heart is meaningful for further understanding the effect of neuroprotection (Pawlos et al., 2021) and cardioprotection.”
BackgroundErdoğan, M. A., Nesil, P., Altuntas, I., Şirin, C., Uyanıkgil, Y., & Erbaş, O. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.013 · Cited by 15
Gholami, M., Coleman‐Fuller, N., Salehirad, M., Darbeheshti, S., & Motaghinejad, M. (2024) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_5_23 · Cited by 16
“[197] In addition to inhibiting SGLT2, gliflozins have an affinity for inhibiting the SGLT1 receptor.”
BackgroundLinks Between Cellular Energy Metabolism and Pain Sensation
Li, X., Zhao, Z., Ke, Y., Jiang, Y., Liu, Y., & Liu, Z. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007096 · Cited by 17
“26 9.”
CCL7 promotes macrophage polarization and synovitis to exacerbate rheumatoid arthritis
Chen, J., Shi, S., Li, X., Gao, F., Zhu, X., Feng, R., Hu, K., Li, Y., Chen, S., Zhang, R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112177 · Cited by 20
“27,28 Our findings indicated a signifi-cant increase in the phosphorylation levels of JAK2 and STAT1 proteins in macrophages stimulated by rmCCL7.”
The role of diabetes mellitus on delirium onset: a systematic review and meta-analysis
Komici, K., Fantini, C., Santulli, G., Bencivenga, L., Femminella, G. D., Guerra, G., Mone, P., & Rengo, G. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02782-w · Cited by 17
“SGLT2-i improves blood-brain barrier, astrocytes, microglia, and oligodendrocytes functioning contributing to amelioration of cognitive performance [119].”
Acetyl-CoA carboxylase activation disrupts iron homeostasis to drive ferroptosis
Han, Z., Han, S., Fang, X., Lu, M., Mao, Y., Shi, L., Song, J., Wang, T., Xiao, J., Xiang, L., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.05.421 · Cited by 15
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
Scheen, A. J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2210673 · Cited by 17
“Preliminary data suggested that SGLT2is could also exert some protection against degenerative neurological disease [112,113], findings that should be confirmed in larger well-matched observational cohort studies and specifically”
ResultCorraliza-Gómez, M., Vargas-Soria, M., & García-Alloza, M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00894-1 · Cited by 16
Kim, D. H., Lee, M. J., Kang, D., Lee, J. Y., Park, S., Khang, A. R., Bae, J. H., Kim, J. Y., Kim, S. H., Kang, Y. H., et al. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46110737 · Cited by 14
“SGLTs occur naturally in the mammalian brain, and SGLT2 inhibitors are lipid-soluble and can easily cross the blood– brain barrier [35,36].”
Cannarella, R., Rubulotta, M., Cannarella, V., Vignera, S. L., & Calogero, A. E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.010 · Cited by 15
Hsieh, C., & Sung, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010351 · Cited by 15
“The inhibition of SGLT1 may thus have a neuroprotective effect by reducing the blood–brain barrier’s permeability and cerebral edema, thereby mitigating the stroke burden in diabetic patients with CKD [49,51].”
BackgroundIncidence, Clinical Correlates, and Prognostic Impact of Dementia in Heart Failure
Ren, Q. W., Teng, T. K., Tse, Y.-K., Tay, W. T., Li, H., Tromp, J., Yu, S.-Y., Hung, D., Wu, M., Chen, C., et al. (2023) · JACC Asia · doi:10.1016/j.jacasi.2022.09.016 · Cited by 14
Song, K., Choi, J., Jeong, D., Shin, D., Ah, Y., Lee, K., & Choi, K. H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1695075 · Cited by 15
Sodium-Glucose Cotransporter-2 Inhibitors in Depression
Liebers, D. T., Ebina, W., & Iosifescu, D. V. (2023) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000374 · Cited by 13
Metadata
- Authors
- Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P.
- Affiliations
- Medical University of Lodz (PL)
- Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Kniaziewicza 1/5, 91-347 Lodz, Poland
- Corresponding author
- Broncel, Marlena
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-11-28
- Volume
- 26
- Issue
- 23
- Pages
- 7213
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8659196
- OpenAlex
- W3214770882
- Semantic Scholar
- d4fddd52e53127993c142ff6d31526f815eb1c00
- Cited by
- 304
- References
- 124
- Citations by year
- 2026: 66 · 2025: 92 · 2024: 71 · 2023: 50 · 2022: 25
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- SGLT2 inhibitors, neuroprotection, type 2 diabetes, cognitive impairment, cardiovascular disease, anti-inflammatory activity, NLRP3 inflammasome, cerebral blood flow, neurovascular unit, blood-brain barrier, acetylcholinesterase inhibition, brain-derived neurotrophic factor, atherosclerosis
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Brain, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neuroprotective Agents, Atherosclerosis, Sodium-Glucose Transporter 2, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.